SAN DIEGO, Dec. 14, 2020 /PRNewswire/ -- Biocept, Inc.
(Nasdaq: BIOC), a leading commercial provider of molecular
diagnostic assays, products and services designed to provide
physicians with clinically actionable information to improve
patient outcomes, announces that it has received more than 150,000
samples for COVID-19 RT-PCR testing to date and has continued to
report the vast majority of results to customers within 48 hours of
receiving a sample. The Company also announces the successful
relocation to its new corporate headquarters and molecular
laboratory facility in San Diego.
"All clinical operations at the new facility are fully
functioning, including our newly designed state-of-art
CLIA-certified and CAP-accredited laboratory. We are pleased
with the smooth transition, and our ability to seamlessly continue
serving physicians and patients with both oncology and COVID-19
testing," said Biocept CFO and SVP of Operations Tim Kennedy. "Our new facility was
designed specifically to align with our commercial, development and
administrative needs, with the bonus of an expected 20% annualized
reduction in rent and other facility costs."
About Biocept
Biocept, Inc. is a molecular diagnostics
company with commercialized assays for lung, breast, gastric,
colorectal and prostate cancers, and melanoma. The Company uses its
proprietary liquid biopsy technology to provide physicians with
clinically actionable information for treating and monitoring
patients diagnosed with cancer. The Company's patented Target
Selector™ liquid biopsy technology platform captures and analyzes
tumor-associated molecular markers in both circulating tumor cells
(CTCs) and in circulating tumor DNA (ctDNA). With thousands of
tests performed, the platform has demonstrated the ability to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic options.
Additionally, Biocept is offering nationwide COVID-19
polymerase chain reaction (PCR) testing to support public health
efforts during this unprecedented pandemic. For more
information, please visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This
release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations
reflected in the forward-looking statements and the assumptions
upon which they are based are reasonable, we can give no assurance
that such expectations and assumptions will prove to have been
correct. Forward-looking statements are generally identifiable by
the use of words like "designed to" and "expect" or the negative of
these words or other variations on these words or comparable
terminology. To the extent that statements in this release are not
strictly historical, including without limitation statements
regarding expected rent and facility costs for Biocept's new
corporate headquarters and molecular laboratory facility and the
ability of Biocept's platform to identify cancer mutations and
alterations to inform physicians about a patient's disease and
therapeutic options, such statements are forward-looking, and are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. The reader is cautioned
not to put undue reliance on these forward-looking statements, as
these statements are subject to numerous risks and uncertainties,
including the risk that the Company's products and services will
not perform as expected and the risk that the Company will not
realize its expected reduction in rent and other facility
costs. These and other factors are described in greater
detail in the Company's filings with the Securities and Exchange
Commission (SEC), including under the caption "Risk Factors" of the
Company's quarterly report on Form 10-Q for the quarter ended
September 30, 2020, as filed with the
SEC on November 16, 2020. The effects
of such risks and uncertainties could cause actual results to
differ materially from the forward-looking statements contained in
this release. We do not plan to update any such forward-looking
statements and expressly disclaim any duty to update the
information contained in this press release except as required by
law. Readers are advised to review our filings with the SEC, which
can be accessed over the Internet at the SEC's website located at
www.sec.gov.
Investor Contact:
LHA Investor
Relations
Jody Cain
Jcain@lhai.com
310-691-7100
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biocept-provides-business-update-301191777.html
SOURCE Biocept, Inc.